NMDA receptor inhibitors/alpha7-nicotinic acetylcholine receptor inhibitors (Naprogenix/Ceptaris)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug NameNMDA receptor inhibitors/alpha7-nicotinic acetylcholine receptor inhibitors (Naprogenix/Ceptaris)
Drug Alias NameNMDA receptor inhibitors/alpha7-nicotinic acetylcholine receptor agonists (Naprogenix/Yaupon Pharmaceuticals)
ClassificationSmall moleculesNatural product/Extract
Mechanisms of ActionNicotinic receptors agonistsGlutamate [NMDA] receptor antagonists
TargetsGlutamate [NMDA] receptorNicotinic receptors
Therapy Area/IndicationsNerve Degeneration
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesNaprogenix Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNaprogenix IncCeptaris Therapeutics
Active IndicationsN/A
Inactive IndicationsNerve Degeneration

Other Information

ATC CodeN/A
Related LinksN/A